A randomized, double-blind study to investigate the effect of GK Activator (2) [RO 4389620] on QT interval following short-term multiple doses in patients with type 2 diabetes mellitus
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Piragliatin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Roche
- 23 Feb 2010 Actual initiation date (Mar 2006) added as reported by Roche record.
- 08 Jan 2008 New trial record.